









PIPELINE

Candidate: Lasofoxifene – Oral SERM

In Planning
Enrollment Complete
Potentially Registrational

	Preclinical	Phase 1	Phase 2	Phase 3/4	
<ul style="list-style-type: none"> • Monotherapy •• Combination Therapy 					
▶ Breast Cancer					
•	ELAINE 1: Lasofoxifene vs. Fulvestrant 				<input type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/>
••	ELAINE 2: Laso + Abemaciclib 				<input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/> 
•	ELAINE 3: Lasofoxifene vs. Fulvestrant 				<input checked="" type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/>
••	ELAINE 4: Laso + CDK 4/6 Inhibitor 				<input checked="" type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/>
••	Laso + mTOR Inhibitor				<input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> 
••	Laso + AKT Inhibitor				<input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
▶ Treatment Resistant Tumors (non-ESR1^{mut}) and ESR1^{mut}					
•	Laso vs. Fulv				
••	Laso + Palbo vs. Fulv + Palbo				
▶ Gynecological Cancer					
•/••	Lasofoxifene – Endometrial Cancer				
▶ ESR1 Assay					
	Research Assay		Clinical Trial Assay (CTA)	CTA/CDx	